{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:03:59Z","timestamp":1761563039782},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,16]]},"DOI":"10.7759\/cureus.56302","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T06:55:30Z","timestamp":1710658530000},"source":"Crossref","is-referenced-by-count":1,"title":["Extensive-Disease Small-Cell Lung Cancer With Severe Immune-Related Adverse Events Due to Atezolizumab Maintaining a Complete Response for Two Years: A Case Report"],"prefix":"10.7759","author":[{"given":"Sayaka","family":"Kudo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiki","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (Caspian): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman JW","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, et al.. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (Caspian): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021, 22:51-65. 10.1016\/S1470-2045(20)30539-8","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu SV","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, et al.. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021, 39:619-30. 10.1200\/JCO.20.01055","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski MA","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, et al.. Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol. 2023, 9:527-35. 10.1001\/jamaoncol.2022.7711","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025795","article-title":"Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: a case report and literature review","volume":"100","author":"Huang X","year":"2021","unstructured":"Huang X, Yang M, Wang L, Li L, Zhong X. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: a case report and literature review. Medicine (Baltimore). 2021, 100:10.1097\/MD.0000000000025795","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100074","article-title":"Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1\/programmed death-ligand 1 blockade in SCLC","volume":"1","author":"Ricciuti B","year":"2020","unstructured":"Ricciuti B, Naqash AR, Naidoo J, et al.. Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1\/programmed death-ligand 1 blockade in SCLC. JTO Clin Res Rep. 2020, 1:10.1016\/j.jtocrr.2020.100074","journal-title":"JTO Clin Res Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15010","article-title":"Relationship between immune-related adverse events and treatment effectiveness in extensive-disease small-cell lung cancer","volume":"14","author":"Yokoo K","year":"2023","unstructured":"Yokoo K, Kitamura Y, Suzuki K, et al.. Relationship between immune-related adverse events and treatment effectiveness in extensive-disease small-cell lung cancer. Thorac Cancer. 2023, 14:2251-8. 10.1111\/1759-7714.15010","journal-title":"Thorac Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13638","article-title":"Prevalence and clinical characteristics of fulminant type\u20091 diabetes mellitus in Korean adults: a multi-institutional joint research","volume":"13","author":"Song SO","year":"2022","unstructured":"Song SO, Yun JS, Ko SH, et al.. Prevalence and clinical characteristics of fulminant type\u20091 diabetes mellitus in Korean adults: a multi-institutional joint research. J Diabetes Investig. 2022, 13:47-53. 10.1111\/jdi.13638","journal-title":"J Diabetes Investig"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2008.05.003","article-title":"Fulminant type 1 diabetes in Caucasians: a report of three cases","volume":"34","author":"Moreau C","year":"2008","unstructured":"Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, Chaillous L, Cariou B. Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab. 2008, 34:529-32. 10.1016\/j.diabet.2008.05.003","journal-title":"Diabetes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.04.005","article-title":"Fulminant type 1 diabetes: report of a new French Caucasian case and recent findings","volume":"46","author":"Le Lepvrier AL","year":"2020","unstructured":"Le Lepvrier AL, Leysour de Rohello F, Brunel V, Prevost G. Fulminant type 1 diabetes: report of a new French Caucasian case and recent findings. Diabetes Metab. 2020, 46:174-6. 10.1016\/j.diabet.2018.04.005","journal-title":"Diabetes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13807","article-title":"Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment","volume":"13","author":"Hatayama S","year":"2022","unstructured":"Hatayama S, Kodama S, Kawana Y, et al.. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment. J Diabetes Investig. 2022, 13:1458-60. 10.1111\/jdi.13807","journal-title":"J Diabetes Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12024","article-title":"Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa A","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T, et al.. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012, 3:536-9. 10.1111\/jdi.12024","journal-title":"J Diabetes Investig"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.685","article-title":"Atezolizumab-induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation","volume":"8","author":"Nishioki T","year":"2020","unstructured":"Nishioki T, Kato M, Kataoka S, Miura K, Nagaoka T, Takahashi K. Atezolizumab-induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation. Respirol Case Rep. 2020, 8:10.1002\/rcr2.685","journal-title":"Respirol Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino MC","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, et al.. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023, 41:1992-8. 10.1200\/JCO.22.01989","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 Study","volume":"41","author":"Novello S","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, et al.. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 Study. J Clin Oncol. 2023, 41:1999-2006. 10.1200\/JCO.22.01990","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 67:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman K","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CE. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018, 103:3144-54. 10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2213","article-title":"Immune checkpoint inhibitors and risk of type 1 diabetes","volume":"45","author":"Chen X","year":"2022","unstructured":"Chen X, Affinati AH, Lee Y, et al.. Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care. 2022, 45:1170-6. 10.2337\/dc21-2213","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette JM","year":"2019","unstructured":"de Filette JM, Pen JJ, Decoster L, et al.. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019, 181:363-74. 10.1530\/EJE-19-0291","journal-title":"Eur J Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa A","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, et al.. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018, 3:10.1172\/jci.insight.59125","journal-title":"JCI Insight"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/228302-extensive-disease-small-cell-lung-cancer-with-severe-immune-related-adverse-events-due-to-atezolizumab-maintaining-a-complete-response-for-two-years-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T06:55:34Z","timestamp":1710658534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/228302-extensive-disease-small-cell-lung-cancer-with-severe-immune-related-adverse-events-due-to-atezolizumab-maintaining-a-complete-response-for-two-years-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.56302","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,16]]}}}